{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:25Z","timestamp":1786982725409,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00947-7","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:33:32Z","timestamp":1778070812000},"page":"1675-1689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adherence, Persistence, and Safety of Risdiplam in Spinal Muscular Atrophy: A Population-Based Cohort Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3169-5253","authenticated-orcid":false,"given":"Maria","family":"Chovi-Trull","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9272-895X","authenticated-orcid":false,"given":"Nancy C.","family":"\u00d1ungo-Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-6388","authenticated-orcid":false,"given":"Karolina A.","family":"Aragon-Gawinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3864-7374","authenticated-orcid":false,"given":"Inmaculada","family":"Pitarch-Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-2341","authenticated-orcid":false,"given":"Asunci\u00f3n","family":"Albert-Mar\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Pellicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-6198","authenticated-orcid":false,"given":"Jos\u00e9 L.","family":"Poveda-Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-9112","authenticated-orcid":false,"given":"Mar\u00eda D.","family":"Edo-Solsona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-7938","authenticated-orcid":false,"given":"Juan F.","family":"V\u00e1zquez-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"947_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-022-03671-x","volume":"22","author":"JW Day","year":"2022","unstructured":"Day JW, Howell K, Place A, Long K, Rossello J, Kertesz N, et al. Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr. 2022;22:632. https:\/\/doi.org\/10.1186\/s12887-022-03671-x.","journal-title":"BMC Pediatr"},{"issue":"15","key":"947_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511939","volume":"24","author":"H Nishio","year":"2023","unstructured":"Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci. 2023;24(15):11939. https:\/\/doi.org\/10.3390\/ijms241511939.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"947_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2217\/fnl.13.58","volume":"9","author":"UR Monani","year":"2014","unstructured":"Monani UR, De Vivo DC. Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond. Future Neurol. 2014;9(1):49\u201365. https:\/\/doi.org\/10.2217\/fnl.13.58.","journal-title":"Future Neurol"},{"key":"947_CR4","unstructured":"CIMA. FICHA TECNICA SPINRAZA 12 MG SOLUCI\u00d3N INYECTABLE [Internet]. [cited 2025 Aug 25]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1171188001\/FT_1171188001.html"},{"key":"947_CR5","unstructured":"CIMA. FICHA TECNICA ZOLGENSMA 2 x 10e13 GENOMAS VECTORIALES\/ML SOLUCION PARA PERFUSION [Internet]. [cited 2025 Aug 25]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1201443001\/FT_1201443001.html"},{"key":"947_CR6","unstructured":"CIMA. FICHA TECNICA EVRYSDI 0,75 mg\/ml POLVO PARA SOLUCION ORAL [Internet]. [cited 2025 Aug 25]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1211531001\/FT_1211531001.html"},{"issue":"7","key":"947_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMoa2410120","volume":"393","author":"RS Finkel","year":"2025","unstructured":"Finkel RS, Servais L, Vlodavets D, et al. Risdiplam in presymptomatic spinal muscular atrophy. N Engl J Med. 2025;393(7):671\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2410120.","journal-title":"N Engl J Med"},{"issue":"6","key":"947_CR8","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1007\/s12325-024-02850-9","volume":"41","author":"ED Pineda","year":"2024","unstructured":"Pineda ED, To TM, Dickendesher TL, Shapouri S, Iannaccone ST. Adherence and persistence among Risdiplam-treated individuals with spinal muscular atrophy: a retrospective claims analysis. Adv Ther. 2024;41(6):2446\u201359. https:\/\/doi.org\/10.1007\/s12325-024-02850-9.","journal-title":"Adv Ther"},{"issue":"3","key":"947_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nrl.2021.07.008","volume":"37","author":"I Pitarch Castellano","year":"2022","unstructured":"Pitarch Castellano I, Cabrera-Serrano M, Calvo Medina R, et al. Consenso Delphi de las recomendaciones para el tratamiento de los pacientes con atrofia muscular espinal en Espa\u00f1a (consenso RET-AME). Neurologia. 2022;37(3):216\u201328. https:\/\/doi.org\/10.1016\/j.nrl.2021.07.008.","journal-title":"Neurologia"},{"issue":"9","key":"947_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1080\/03007995.2018.1477747","volume":"34","author":"CA Forbes","year":"2018","unstructured":"Forbes CA, Deshpande S, Sorio-Vilela F, et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin. 2018;34(9):1613\u201325. https:\/\/doi.org\/10.1080\/03007995.2018.1477747.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"947_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/ene.15499","volume":"30","author":"E Mercuri","year":"2023","unstructured":"Mercuri E, Baranello G, Boespflug-Tanguy O, et al. Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2023;30(7):1945\u201356. https:\/\/doi.org\/10.1111\/ene.15499.","journal-title":"Eur J Neurol"},{"key":"947_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13557-4","author":"P Alonge","year":"2025","unstructured":"Alonge P, Urbano G, Gadaleta G. Safety and effectiveness of risdiplam in adults with spinal muscular atrophy: a systematic review. J Neurol. 2025. https:\/\/doi.org\/10.1007\/s00415-025-13557-4.","journal-title":"J Neurol"},{"key":"947_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-024-03399-0","volume":"19","author":"A Patel","year":"2024","unstructured":"Patel A, Toro W, Yang M, et al. Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis. Orphanet J Rare Dis. 2024;19:1\u201311. https:\/\/doi.org\/10.1186\/s13023-024-03399-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"947_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/22143602251361190","volume":"12","author":"C Puig-Ram","year":"2025","unstructured":"Puig-Ram C, Segovia S, Garcia-Uzquiano R, et al. Real-world data on spinal muscular atrophy in Spain: insights from over 500 individuals in the CuidAME project. Journal of Neuromuscular Diseases. 2025;12(6):837\u201348. https:\/\/doi.org\/10.1177\/22143602251361190.","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"12","key":"947_CR15","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1007\/s12325-021-01938-w","volume":"38","author":"M Gauthier-Loiselle","year":"2021","unstructured":"Gauthier-Loiselle M, Cloutier M, Toro W, et al. Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis. Adv Ther. 2021;38(12):5809\u201328. https:\/\/doi.org\/10.1007\/s12325-021-01938-w.","journal-title":"Adv Ther"},{"issue":"3","key":"947_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12325-022-02376-y","volume":"40","author":"D Fox","year":"2023","unstructured":"Fox D, To TM, Seetasith A, Patel AM, Iannaccone ST. Adherence and persistence to Nusinersen for spinal muscular atrophy: a US claims-based analysis. Adv Ther. 2023;40(3):903\u201319. https:\/\/doi.org\/10.1007\/s12325-022-02376-y.","journal-title":"Adv Ther"},{"issue":"5","key":"947_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3233\/JND-210768","volume":"9","author":"L Elman","year":"2022","unstructured":"Elman L, Youn B, Proud CM, et al. Real-world adherence to Nusinersen in adults with Spinal Muscular Atrophy in the US: a multi-site chart review study. J Neuromuscul Dis. 2022;9(5):655\u201360. https:\/\/doi.org\/10.3233\/JND-210768.","journal-title":"J Neuromuscul Dis"},{"key":"947_CR18","doi-asserted-by":"publisher","DOI":"10.64898\/2026.03.11.26348135","author":"K Aragon-Gawinska","year":"2026","unstructured":"Aragon-Gawinska K, Nungo Garzon NC, Muelas N, et al. Long-term adherence, safety and effectiveness of nusinersen in spinal muscular atrophy patients: a population-based study. medRxiv. 2026. https:\/\/doi.org\/10.64898\/2026.03.11.26348135.","journal-title":"medRxiv"},{"issue":"9","key":"947_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/children12091170","volume":"12","author":"I Pitarch-Castellano","year":"2025","unstructured":"Pitarch-Castellano I, \u00d1ungo-Garz\u00f3n NC, Aragon-Gawi\u0144ska K, Ib\u00e1\u00f1ez-Albert E, V\u00e1zquez-Costa JF, Sevilla T. Neurofilaments as biomarkers of the efficacy of Risdiplam treatment in early SMA phenotypes diagnosed by newborn screening. Children. 2025;12(9):1170. https:\/\/doi.org\/10.3390\/children12091170.","journal-title":"Children"},{"issue":"12","key":"947_CR20","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40261-023-01320-420","volume":"43","author":"W Zhuang","year":"2023","unstructured":"Zhuang W, Lu M, Wu Y, et al. Safety concerns with nusinersen, risdiplam, and onasemnogene abeparvovec in spinal muscular atrophy: a real-world pharmacovigilance study. Clin Drug Investig. 2023;43(12):949\u201362. https:\/\/doi.org\/10.1007\/s40261-023-01320-420.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"947_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03442-0","volume":"19","author":"G Severa","year":"2024","unstructured":"Severa G, Alfaro MdelC, Alimi Ichola C, Shoaito H, Souvannanorath S, Authier FJ, et al. Risdiplam: therapeutic effects and tolerability in a small cohort of 6 adult type 2 and type 3 SMA patients. Orphanet J Rare Dis. 2024;19(1):430. https:\/\/doi.org\/10.1186\/s13023-024-03442-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"947_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","volume":"17","author":"A Hahn","year":"2022","unstructured":"Hahn A, G\u00fcnther R, Ludolph A, et al. Short-term safety results from compassionate use of Risdiplam in patients with Spinal Muscular Atrophy in Germany. Orphanet J Rare Dis. 2022;17(1):276. https:\/\/doi.org\/10.1186\/s13023-022-02420-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"947_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JND-230197","volume":"11","author":"B Sitas","year":"2024","unstructured":"Sitas B, Hancevic M, Bilic K, Bilic H, Bilic E. Risdiplam real world data - looking beyond motor neurons and motor function measures. J Neuromuscul Dis. 2024;11(1):75\u201384. https:\/\/doi.org\/10.3233\/JND-230197.","journal-title":"J Neuromuscul Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00947-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:15Z","timestamp":1784819475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00947-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00947-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maria Chovi-Trull has nothing to disclose. Nancy C. \u00d1ungo-Garz\u00f3n receives funding from the CUIDAME project (2019-027-1). Karolina A. Aragon-Gawinska is funded by the CIAPOT\/2023\/25. The Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER) is an initiative of Instituto de Salud Carlos III. Inmaculada Pitarch-Castellano is a member of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD) and has received personal fees for consulting and training activities from Biogen, Roche, and Novartis outside the submitted work. Asunci\u00f3n Albert-Mar\u00ed has nothing to disclose. Javier Garc\u00eda-Pellicer has nothing to disclose. Jos\u00e9 L. Poveda-Andr\u00e9s has nothing to disclose. Mar\u00eda D. Edo-Solsona has nothing to disclose. Juan F. V\u00e1zquez-Costa is a member of the advisory board of CUIDAME. He is funded by grants from the Instituto de Salud Carlos III (PI24\/01512, DTS23\/00112) and has received personal fees from Biogen, Roche, and Novartis outside the submitted work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Clinical Research Ethics Committee of Hospital Universitari i Polit\u00e8cnic La Fe and conducted in accordance with the Declaration of Helsinki. Due to its non-interventional observational design based on routinely collected data, informed consent was not required, as determined by the Ethics Committee.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}